IPSEN : The FDA approves Somatuline® Depot (lanreotide) Injection Extended Dosing Interval as part of Ipsen's Prior Approval Supplement application Ipsen (Euronext: IPN; ADR: IPSEY) announced today ...

In the LOCKCYST I clinical trial, a low dose of Somatuline Depot injection for the treatment of polycystic liver disease was found to be safe and effective, according to published findings.

The Food and Drug Administration has given Cipla its stamp of approval for lanreotide injection. The medication is the generic of Ipsen’s Somatuline Depot. It is indicated for the treatment of ...

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that the U.S. Food and Drug Administration (FDA) has approved a ...

Lanreotide 60mg/0.2mL, 90mg/0.3mL, 120mg/0.5mL; prolonged-release soln for SC inj. Lanreotide, the active component of Somatuline Depot is an octapeptide analog of natural somatostatin. The mechanism ...

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.

What is SOMATULINE® DEPOT (lanreotide) Injection? SOMATULINE DEPOT is a prescription medicine used in adults for: the long-term treatment of people with acromegaly when surgery or radiotherapy have ...

The 16-week study (n=115) enrolled patients with histopathologically-confirmed neuroendocrine tumors and a history of carcinoid syndrome who were treatment-naive or stable on another somatostatin ...

Insulin-like growth factor I and growth hormone levels were adequately controlled on 4-weekly injections in nine patients. In these patients the effect of increasing the time interval between ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) published today new data from seven abstracts to be presented at the hybrid-setting 19 th Annual European Neuroendocrine ...

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...